FDA warned Revitalize Energy that its Revitalize Energizing Eye Drops are an unapproved new drug and misbranded.
What happened
On April 14, 2025, FDA reviewed Revitalize Energy's product labeling, including its website and Facebook posts, for Revitalize Energizing Eye Drops. FDA found the eye drops are intended as a drug, are sold without a prescription, and do not meet the OTC monograph for ophthalmic products because menthol, camphor, caffeine, and taurine are used as active ingredients not permitted for OTC ophthalmic demulcent or vasoconstrictor products, and because labeling claims go beyond allowed uses. FDA also found the label and website use FDA logos and claims such as "FDA COMPLIANT" that falsely suggest FDA approval.
What FDA found
The eye drops are an unapproved new drug sold in interstate commerce without an FDA-approved application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a), 331(d)The eye drops do not meet the OTC ophthalmic monograph M018 because menthol, camphor, caffeine, and taurine are not permitted active ingredients for OTC ophthalmic demulcent or vasoconstrictor products.
FD&C Act section 505G, 21 U.S.C. 355h; M018.12 and M018.18The labeling includes uses not allowed under M018, such as protection from cataracts caused by UV-B rays, "instant energy," and "energizing eye."
M018.60 and M018.75The product is misbranded because its label and website use an FDA logo and claims like "FDA COMPLIANT," "MADE IN A FDA REGISTERED FACILITY," and "FDA GRAS APPROVED" that falsely suggest FDA approval or legal marketability.
FD&C Act section 502(a), 21 U.S.C. 352(a); 21 CFR 207.77(b)The product is misbranded as a nonprescription drug subject to section 505G that does not comply with that section and has no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, including related documentation. If corrections cannot be completed in that time, FDA asks for the reason and a completion date.
Who should pay attention
- retailers and online marketplaces selling eye drops
- companies making OTC ophthalmic products
- brands that use "FDA compliant" or "FDA registered" marketing claims
This is a summary. Read the original letter on fda.gov.